ANI Pharma (ANIP) Misses Q2 EPS by 16c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ANI Pharmaceuticals Reports Second Quarter 2020 Results
August 6, 2020 6:50 AM EDT- Second quarter 2020 net revenues of $48.5 million -
- Nikhil Lalwani named President and CEO, effective September 8, 2020
- Pharmaceutical industry executives, Jeanne Thoma and Tony Pera, join Board of Directors -
BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2020.
Business and Recent Highlights:
Completed comprehensive gap assessment on lead product, Cortrophin®... More